Zum Inhalt springen

TK warnt vor Krankenkassenbeiträgen von 20 Prozent

Der Chef der Krankenkasse TK, Jens Baas, fürchtet, dass die Kosten im Gesundheitssystem ohne Reformen ungebremst weiter steigen werden. In der Legislaturperiode der nächsten Regierung könnten die Krankenkassenbeiträge auf 20 Prozent steigen, sagte Baas der „Süddeutschen Zeitung“. „Das wird in diesem Jahrzehnt noch passieren, wenn der Gesetzgeber nicht gegensteuert“, so Baas. Er sei nicht optimistisch, […] TK warnt vor Krankenkassenbeiträgen von 20 Prozent

Hessen wappnet sich für den Kampf gegen die Maul- und Klauenseuche

Nach Ausbruch der gefährlichen Tierseuche in Brandenburg richtet das Landwirtschaftsministerium einen Appell an die Tierhalter und ergreift erste Maßnahmen. Nach dem Ausbruch der hochansteckenden MKS in Brandenburg wappnet sich Hessen für den Kampf gegen die Tierseuche. Das Landwirtschaftsministerium hat Sofortmaßnahmen ergriffen, um einen möglichen Ausbruch der Tierseuche im Land so schnell wie möglich festzustellen. So […] Hessen wappnet sich für den Kampf gegen die Maul- und Klauenseuche

Nach Ausbruch von Maul- und Klauenseuche: FLI ermittelt Serotyp

Nach dem seit 1988 deutschlandweit ersten Ausbruch der Maul- und Klauenseuche (MKS) in Brandenburg hat das Friedrich-Loeffler-Institut (FLI) den Seroytp des Virus bestimmt. Das teilte das Bundeslandwirtschaftsministerium am Samstagabend mit. Als Serotyp bezeichnet man Variationen innerhalb von Subspezies von Bakterien oder Viren anhand serologischer Tests. Der Serotyp ist ein formales Mittel zur detaillierteren Klassifizierung von […] Nach Ausbruch von Maul- und Klauenseuche: FLI ermittelt Serotyp

Cmbio® Acquires Eagle Genomics‘ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform

Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited (In Administration). Eagle Genomics, founded in 2008 and based in Cambridge, UK is renowned for its enterprise cloud software platform that facilitates data-intensive research in life sciences. The company’s platform provides an intuitive approach to curating, integrating, sharing, analyzing, and valuing complex scientific data. The Asset Sale Agreement includes all intellectual property related to Eagle Genomics‘ business. This strategic transaction aligns well with Cmbio®’s mission to advance multi-omics science and technology, enabling scientists across industry and academia to access its advanced bioinformatics and AI/ML toolbox through scalable, robust and validated software solutions.

Immorta Bio to Present New Data on SenoVax™ and StemCell Revivify™ at Biotech Showcase 2025

Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today that it will present its latest developments at the upcoming Biotech Showcase in San Francisco, CA. The company’s presentation will provide insights into its groundbreaking research and technological advancements aimed at Treating Diseases of Aging and Treating Aging as Disease™. Details of the presentation are as follows: Event: Biotech Showcase 2025 Date: January 14, 2025 Time: 4 PM Pacific Location: Franciscan C, Ballroom Level

Diakonos Oncology to Present at Biotech Showcase 2025

Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced that it will present its latest developments at the Biotech Showcase in San Francisco, CA from January 13-15, 2025. Biotech Showcase is a premier event for private and micro-mid-cap biotechnology companies to highlight their innovation and connect with global investors and engage with executives from prominent biopharmaceutical interests. Diakonos Oncology will be represented by President and Chief Operating Officer Jay Hartenbach, who will be presenting on recent corporate milestones and research developments, including lead product DOC1021, a unique autologous dendritic cell vaccine (DCV), which will begin enrolling patients in its Phase 2 clinical trial for glioblastoma (GBM) in H1 2025 at leading treatment centers across the US. Details of the presentation are as follows: Event: Biotech… 

more »Diakonos Oncology to Present at Biotech Showcase 2025

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac arrhythmias. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is an irrigated, contact-force sensing catheter powered by the TRUPULSE™ Generator, and is fully integrated with the CARTO™ 3 System for electro-anatomical mapping and for tag indexing.1 The company expects TRUPULSE™ Generator hardware compatibility in the first half of 2025. When fully approved, the platform will provide electrophysiologists with the ability to switch between radiofrequency (RF) and pulsed field (PF) energy in the same catheter they know and trust. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is not currently approved in the United States. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is designed on the same platform as the radiofrequency THERMOCOOL SMARTTOUCH™… 

more »Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Milestone in SurVaxM Production for Glioblastoma Treatment

MimiVax, Inc. and UI Pharmaceuticals have announced the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP’s recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients. About SurVaxM SurVaxM is a groundbreaking immunotherapeutic targeting survivin, a cell-survival protein prevalent in glioblastomas and many other cancers. This innovative immunotherapy is engineered to stimulate a patient’s immune system to recognize survivin-expressing cancer cells as foreign, thereby controlling tumor growth and recurrence. Currently, SurVaxM is being evaluated in a randomized Phase 2b clinical trial for glioblastoma at 11 leading cancer centers across the United States. Additional clinical trials are exploring its potential in multiple myeloma, neuro-endocrine tumors (NET), and pediatric relapsed high-grade glioma. MimiVax’s Glioblastoma treatment using… 

more »Milestone in SurVaxM Production for Glioblastoma Treatment

Regor Releases Phase 2a Topline Results for RGT-075

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau.No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo.Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025

Teamwork im Auge: Beim Erkennen von Kontrasten und Bewegungen arbeiten die Nervenzellen zusammen

Forschende der Universitätsmedizin Göttingen (UMG) haben herausgefunden, dass Nervenzellen im Auge natürliche optische Reize aus der Umgebung häufig gemeinsam in Zellgruppen und aufeinander abgestimmt verarbeiten. Die koordinierte Zusammenarbeit der Nervenzellen verstärkt die Signalübertragung bei Szenen mit hohem Kontrast und Bewegungen. Diese Erkenntnisse könnten dazu beitragen, die Behandlung von Blindheit zu verbessern. Unser Sehsinn versorgt uns… Teamwork im Auge: Beim Erkennen von Kontrasten und Bewegungen arbeiten die Nervenzellen zusammen